180 related articles for article (PubMed ID: 31341951)
1. Blood-based monitoring identifies acquired and targetable driver
Medford AJ; Dubash TD; Juric D; Spring L; Niemierko A; Vidula N; Peppercorn J; Isakoff S; Reeves BA; LiCausi JA; Wesley B; Malvarosa G; Yuen M; Wittner BS; Lawrence MS; Iafrate AJ; Ellisen L; Moy B; Toner M; Maheswaran S; Haber DA; Bardia A
NPJ Precis Oncol; 2019; 3():18. PubMed ID: 31341951
[TBL] [Abstract][Full Text] [Related]
2. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Jhaveri K; Eli LD; Wildiers H; Hurvitz SA; Guerrero-Zotano A; Unni N; Brufsky A; Park H; Waisman J; Yang ES; Spanggaard I; Reid S; Burkard ME; Vinayak S; Prat A; Arnedos M; Bidard FC; Loi S; Crown J; Bhave M; Piha-Paul SA; Suga JM; Chia S; Saura C; Garcia-Saenz JÁ; Gambardella V; de Miguel MJ; Gal-Yam EN; Rapael A; Stemmer SM; Ma C; Hanker AB; Ye D; Goldman JW; Bose R; Peterson L; Bell JSK; Frazier A; DiPrimeo D; Wong A; Arteaga CL; Solit DB
Ann Oncol; 2023 Oct; 34(10):885-898. PubMed ID: 37597578
[TBL] [Abstract][Full Text] [Related]
3. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
Park J; Chang ES; Kim JY; Chelakkot C; Sung M; Song JY; Jung K; Lee JH; Choi JY; Kim NY; Lee H; Kang MR; Kwon MJ; Shin YK; Park YH; Choi YL
Breast Cancer Res; 2024 Jan; 26(1):13. PubMed ID: 38238761
[TBL] [Abstract][Full Text] [Related]
4. Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib.
Shishido SN; Masson R; Xu L; Welter L; Prabakar RK; D' Souza A; Spicer D; Kang I; Jayachandran P; Hicks J; Lu J; Kuhn P
NPJ Breast Cancer; 2022 Feb; 8(1):22. PubMed ID: 35181666
[TBL] [Abstract][Full Text] [Related]
5. An Acquired
Hanker AB; Brewer MR; Sheehan JH; Koch JP; Sliwoski GR; Nagy R; Lanman R; Berger MF; Hyman DM; Solit DB; He J; Miller V; Cutler RE; Lalani AS; Cross D; Lovly CM; Meiler J; Arteaga CL
Cancer Discov; 2017 Jun; 7(6):575-585. PubMed ID: 28274957
[TBL] [Abstract][Full Text] [Related]
6. Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer.
Marín A; Mamun AA; Patel H; Akamatsu H; Ye D; Sudhan DR; Eli L; Marcelain K; Brown BP; Meiler J; Arteaga CL; Hanker AB
Cancer Res; 2023 Sep; 83(18):3145-3158. PubMed ID: 37404061
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
[TBL] [Abstract][Full Text] [Related]
8. Identification of Somatically Acquired
Vidula N; Dubash T; Lawrence MS; Simoneau A; Niemierko A; Blouch E; Nagy B; Roh W; Chirn B; Reeves BA; Malvarosa G; Lennerz J; Isakoff SJ; Juric D; Micalizzi D; Wander S; Spring L; Moy B; Shannon K; Younger J; Lanman R; Toner M; Iafrate AJ; Getz G; Zou L; Ellisen LW; Maheswaran S; Haber DA; Bardia A
Clin Cancer Res; 2020 Sep; 26(18):4852-4862. PubMed ID: 32571788
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Determinants of Response to HER Kinase Inhibition in
Smyth LM; Piha-Paul SA; Won HH; Schram AM; Saura C; Loi S; Lu J; Shapiro GI; Juric D; Mayer IA; Arteaga CL; de la Fuente MI; Brufksy AM; Spanggaard I; Mau-Sørensen M; Arnedos M; Moreno V; Boni V; Sohn J; Schwartzberg LS; Gonzàlez-Farré X; Cervantes A; Bidard FC; Gorelick AN; Lanman RB; Nagy RJ; Ulaner GA; Chandarlapaty S; Jhaveri K; Gavrila EI; Zimel C; Selcuklu SD; Melcer M; Samoila A; Cai Y; Scaltriti M; Mann G; Xu F; Eli LD; Dujka M; Lalani AS; Bryce R; Baselga J; Taylor BS; Solit DB; Meric-Bernstam F; Hyman DM
Cancer Discov; 2020 Feb; 10(2):198-213. PubMed ID: 31806627
[No Abstract] [Full Text] [Related]
10. Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.
Sundaresan TK; Dubash TD; Zheng Z; Bardia A; Wittner BS; Aceto N; Silva EJ; Fox DB; Liebers M; Kapur R; Iafrate J; Toner M; Maheswaran S; Haber DA
Breast Cancer Res Treat; 2021 Jul; 188(1):43-52. PubMed ID: 34101078
[TBL] [Abstract][Full Text] [Related]
11. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.
Somlo G; Lau SK; Frankel P; Hsieh HB; Liu X; Yang L; Krivacic R; Bruce RH
Breast Cancer Res Treat; 2011 Jul; 128(1):155-63. PubMed ID: 21499685
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.
Agelaki S; Kalykaki A; Markomanolaki H; Papadaki MA; Kallergi G; Hatzidaki D; Kalbakis K; Mavroudis D; Georgoulias V
PLoS One; 2015; 10(6):e0123683. PubMed ID: 26083256
[TBL] [Abstract][Full Text] [Related]
13. Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.
Kalra R; Chen CH; Wang J; Salam AB; Dobrolecki LE; Lewis A; Sallas C; Yates CC; Gutierrez C; Karanam B; Anurag M; Lim B; Ellis MJ; Kavuri SM
Cancer Res; 2022 Aug; 82(16):2928-2939. PubMed ID: 35736563
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
[TBL] [Abstract][Full Text] [Related]
15. Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.
Fuentes-Antrás J; Martínez-Rodríguez A; Guevara-Hoyer K; López-Cade I; Lorca V; Pascual A; de Luna A; Ramírez-Ruda C; Swindell J; Flores P; Lluch A; Cescon DW; Pérez-Segura P; Ocaña A; Jones F; Moreno F; García-Barberán V; García-Sáenz JÁ
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511178
[TBL] [Abstract][Full Text] [Related]
16. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.
Venetis K; Pepe F; Pescia C; Cursano G; Criscitiello C; Frascarelli C; Mane E; Russo G; Taurelli Salimbeni B; Troncone G; Guerini Rocco E; Curigliano G; Fusco N; Malapelle U
Cancer Treat Rev; 2023 Dec; 121():102642. PubMed ID: 37864956
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S
Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679
[TBL] [Abstract][Full Text] [Related]
18. Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance.
Cheng X; Sun Y; Highkin M; Vemalapally N; Jin X; Zhou B; Prior JL; Tipton AR; Li S; Iliuk A; Achilefu S; Hagemann IS; Edwards JR; Bose R
Cancer Res; 2023 Sep; 83(17):2839-2857. PubMed ID: 37272756
[TBL] [Abstract][Full Text] [Related]
19. Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.
Fernandez-Garcia D; Nteliopoulos G; Hastings RK; Rushton A; Page K; Allsopp RC; Ambasager B; Gleason K; Guttery DS; Ali S; Charles Coombes R; Shaw JA
Br J Cancer; 2022 Nov; 127(10):1858-1864. PubMed ID: 36088510
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S
Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
